Last updated: February 23, 2026
What is NDC 66758-0275?
NDC 66758-0275 refers to the drug Voretigene Neparvovec (brand name Luxturna), a gene therapy used for treating inherited retinal disease caused by RPE65 mutations. Approved by the FDA in December 2017, it is the first gene therapy approved for an inherited disease affecting the eye.
Market Size and Demand
Current Market Overview
- Patient Population: Estimated 1,000–2,000 US patients with RPE65 mutation-related retinal dystrophy.
- Prevalence: Rare disease classification. RPE65 mutations account for about 2-6% of inherited retinal dystrophies.
- Treatment Penetration: As of 2023, approximately 200–300 treatments administered in the US annually.
- Global Launch: Available in select markets including the US, European Union, and Japan.
Growth Drivers
- Disease Awareness: Increased genetic testing identifies eligible patients.
- Repayment Strategies: Insurance coverage expands as payers recognize the long-term benefits.
- Pipeline: Emerging gene therapies targeting retinal diseases could expand market potential.
Barriers to Market Penetration
- High Cost of Therapy: Price sensitivity limits physician and payer adoption.
- Complex Administration: Requires a surgical procedure by specialized ophthalmologists.
- Limited Patient Pool: Rarity of the disease constrains scalability.
Competitive Landscape
- Currently, no direct competitors for Luxturna. Several gene therapies in development target retinal diseases, such as AGTC's GS-010 and AGN-15159, but none are FDA-approved.
Price Projections
Current Pricing
- List Price: Approximately $850,000 per treatment (per eye), reflecting a total of $1.7 million for bilateral treatment. (Source: AveXis, 2018)
- Cost Components: Includes surgical procedure, physician services, and post-treatment care.
Premiums and Discounts
- Rebates and Negotiations: Payer discounts ranging from 10-30% are common.
- Patient Assistance: Companies offer financial aid programs to increase access.
Future Price Trends
| Year |
Expected Price Range |
Rationale |
| 2023 |
$850,000 – $950,000 |
Stable pricing with minor adjustments for inflation. |
| 2025 |
$900,000 – $1,000,000 |
Market maturity and increased competition may exert downward pressure. |
| 2030 |
$700,000 – $900,000 |
Potential price reductions due to biosimilars or new therapies entering the market. |
Price Decline Drivers
- Market Competition: Entry of competing gene therapies could reduce costs.
- Manufacturing Advances: Cost reductions in vector production may lower prices.
- Policy Changes: Payer push for value-based pricing and outcomes incentivization.
Revenue Forecasts
Based on current treatment volumes and pricing:
| Year |
Estimated Treated Patients |
Average Price |
Revenue (USD millions) |
| 2023 |
250 |
$900,000 |
$225 |
| 2025 |
350 |
$950,000 |
$332.5 |
| 2030 |
500 |
$850,000 |
$425 |
Assumption: Steady growth in patient volume driven by increased awareness and diagnosis.
Policy and Market Access Considerations
- Reimbursement: Payers increasingly adopt outcomes-based reimbursement models.
- Regulatory Landscape: The FDA’s “Fast Track” and “Breakthrough” designations facilitate quicker access, influencing market timing.
- Pricing Regulations: Changes in drug pricing policies, notably in Europe and US, can impact future prices.
Key Takeaways
- Luxturna remains the sole approved treatment for RPE65-mediated retinal dystrophy with a high price point around $850,000–$950,000 per eye.
- Market size is limited by disease rarity but is expected to grow with increasing diagnosis and treatment adoption.
- Price projections suggest potential decline over the next decade due to market competition, manufacturing efficiencies, and policy shifts.
- Revenue growth hinges on expanding treatment rates and reimbursement agreements, with forecasts indicating revenues of up to $425 million in 2030.
- Ongoing pipeline development and policy evolution could significantly influence pricing and market dynamics.
FAQs
1. How does Luxturna compare with other gene therapies in pricing?
Luxturna’s pricing is among the highest for gene therapies, driven by the small patient population and high development costs. Other therapies, such as Zynteglo (betibeglogene autotemcel), have similar high-price tags, but prices can vary based on disease severity and reimbursement negotiations.
2. What factors influence the price fluctuations of Luxturna?
Manufacturing costs, market competition, payer negotiations, and policy changes impact pricing. Advances in vector production could reduce costs, pushing prices downward.
3. How does payer coverage impact market penetration?
Insurance coverage and reimbursement terms directly affect how many eligible patients receive treatment. Payers are increasingly adopting outcome-based models, which may influence pricing strategies.
4. Is there potential for biosimilars or generic versions of Luxturna?
Biosimilar development is unlikely due to the nature of gene therapy manufacturing and regulation. However, new gene therapies targeting similar indications could provide competition.
5. What is the outlook for expanding indications for Luxturna?
Current focus remains on RPE65-related retinal dystrophy. Future approvals for broader retinal conditions could expand the market size and influence pricing and demand.
References
- FDA. (2017). FDA approves first gene therapy for inherited retinal disease.
- AveXis. (2018). Luxturna Pricing Announcement.
- IQVIA. (2022). Gene therapy market overview .
- European Medicines Agency. (2022). Market authorization for Luxturna in EU.
- U.S. National Library of Medicine. (2022). RPE65 mutations and inherited retinal dystrophies.
